血栓相关分子标志物在糖尿病血瘀证中的临床意义  

Clinical Significance of Thrombo Molecular Markers in Blood-stasis Syndrome in Diabetes Mellitus

作　　者：石志芸[1] 施赛珠[1] 陈剑秋[1] 张茂华[1] 孙爱红[1] 

机构地区：[1]上海医科大学附属华山医院,上海市乌鲁木齐路12号200040

出　　处：《中医杂志》1999年第9期554-555,共2页Journal of Traditional Chinese Medicine

摘　　要：以血浆α-颗粒膜蛋白(GMP—140)、组织型纤溶酶原激活剂(tPA)、纤溶酶原激活物抑制剂(PAI-Ⅰ)、凝血酶-抗凝血酶Ⅲ复合物(TAT)和血浆纤溶酶-α_2抗纤溶酶抑制物(PAP)、内皮素(ET)等血栓前状态分子标志物,探讨与糖尿病血瘀证的相关性。结果显示,糖尿病血瘀证患者存在着血小板活化、内皮细胞受损、纤溶酶的改变,其血MGMP—140、TAT、PAP、ET均高于非血瘀证和正常对照组。提示血小板活化、内皮细胞受损、凝血/纤溶平衡的改变有利于血瘀证的发生。糖尿病血瘀证的病理生理机制与血小板、内皮细胞、凝血、纤溶等改变皆有关。By applying the thrombo pre molecular markers, including plasmal GMP - 140, tPA, PAI - I TAT, PAP, ET, their correlation with blood stasis type diabetes were explored. Results showed that, the diabetic with blood -stasis type revealed the activation of platelets, injury of endothelial cells, changes of fibrinolysin. Their plasmal GMP-140, TAT, PAP, ET were all higher than that of the control group, indicating that the activation of platelets, injury of endothelial cells, and changes in the balance of blood coagulation/fibrinolysis are likely to benefit the incidence of blood stasis. The pathophysiological mechanism in blood stasis type diabetes is related to the changes in platelet, endothelial cells, blood coagulation and fibrinolysis.

关 键 词：糖尿病 血瘀 诊断 GMP-140 TPA 

分 类 号：R259.871[医药卫生—中西医结合]